Advertisement

Search Results

Advertisement



Your search for Julia Cipriano, MS matches 9 pages

Showing 1 - 9


issues in oncology

Can GLP-1 Receptor Agonists Prevent Obesity-Associated Cancers in Patients With Type 2 Diabetes?

Based on the results of a retrospective U.S. population–based cohort study, which were reported in JAMA Network Open by Wang et al, treatment with glucagon-like peptide 1 (GLP-1) receptor agonists vs insulins seemed to be associated with a decreased risk of developing specific obesity-associated...

head and neck cancer

Nasopharyngeal Carcinoma: Adding Sintilimab to Standard Chemoradiotherapy for Locoregionally Advanced Disease

Based on the results of the Chinese multicenter phase III CONTINUUM trial, which were reported in The Lancet by Liu et al, the addition of the PD-1 inhibitor sintilimab to standard chemoradiotherapy seemed to improve event-free survival—albeit with more frequent but manageable adverse events—in...

gynecologic cancers
leukemia
survivorship

Risk of Adverse Obstetric Outcomes in Adolescent and Young Adult Cancer Survivors

In an English and Welsh study (The Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Sunguc et al found that cervical cancer and leukemia survivors have a heightened risk of experiencing several serious obstetric complications. “Therefore, any pregnancy [in these...

hepatobiliary cancer

Nonplatinum Chemotherapy Regimen for Advanced Cholangiocarcinoma

Based on the results of the multicenter phase II NIFE-AIO-YMO HEP-0315 trial, which were reported in the Journal of Clinical Oncology by Ettrich et al, first-line palliative treatment with nanoliposomal irinotecan plus fluorouracil and leucovorin appears to be safe and active in patients with...

colorectal cancer

Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP

As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...

skin cancer

Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma

As reported at the 2024 ASCO Annual Meeting (Abstract 9500) and in The New England Journal of Medicine by Georgina V. Long, MD, PhD, and colleagues, the final, 8-year follow-up analysis of the phase III COMBI-AD trial has shown continued improvements in relapse-free and distant metastasis–free...

breast cancer

Socioeconomic Disparities in Quality of Life After Early-Stage Breast Cancer Diagnosis

As reported in the Journal of Clinical Oncology by Sandoval et al, after a diagnosis of early-stage breast cancer, the magnitude of preexisting socioeconomic status–related inequalities in quality of life increased over time for patients in the multicentric French CANTO cohort.  “When we talk about ...

gastrointestinal cancer
neuroendocrine tumors

Advanced Neuroendocrine Tumors: Adding Lu-177 Dotatate to Standard First-Line Therapy

As reported in The Lancet by Simron Singh, MD, MPH, FRCPC, and colleagues, primary results of the international, multicenter, randomized phase III NETTER-2 study have shown significantly improved progression-free survival with the addition of the radioligand lutetium-177 dotatate (Lu-177 dotatate)...

multiple myeloma
breast cancer
bladder cancer
gynecologic cancers
skin cancer
pancreatic cancer

NCCN Clinical Practice Guidelines in Oncology: 2024 Updates

The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...

Advertisement

Advertisement




Advertisement